MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Aclaris Therapeutics, Inc. (NASDAQ: ACRS)*
Organization & Developments: Aclaris
Parents
Aclaris Therapeutics, Inc. (NASDAQ: ACRS)*
Children
2017: Aclaris - FDA Approved Its First Drug, And What Now? - Aclaris Therapeutics (NASDAQ:ACRS)
2017: Aclaris: PDUFA Ahead, A Long-Short Complementary Strategy - Aclaris Therapeutics (NASDAQ:ACRS)
2018: Aclaris Therapeutics: A Promising Dermatology Buy In 2018_seekingalpha.com
2019: Aclaris hammered as hair loss drug flops in PhII, days after FDA took issue with Eskata ads – Endpoints News
2019: Aclaris Therapeutics: Buy, Sell Or Hold?_seekingalpha.com
2019: Aclaris’ lead drug clears pivotal study – Endpoints News
2019: With One Late-Stage Study Out Of The Way, Aclaris Moves One Inch Closer To Commercialization_seekingalpha.com
2021: Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure
2023: Aclaris Therapeutics Has Strong Upside Potential, But Shares Could Be Lower_ seekingalpha.com
Aclaris Therapeutics is a stealth pharmaceutical company.
Manufactures and develops novel dermatological therapies
Jumps
*Key People: Aclaris
Finance & Acquisitions: Aclaris